Arga has developed a new system focused to improve the effectiveness of cardiac ablation for the treatment of Atrial Fibrillation (AF). AF is the second cause of stroke and cardiac ablation is the only treatment today recommended for those that fail treatment with anti-arrhythmic drugs. Despite good acute outcomes of current ablation technologies, the recurrence of AF occurs in 30 to 50% of patients within a year, demanding a new procedure.
Arga has developed a new source of energy that improves on safety and effectiveness of procedure, without having to change the medical procedure or patient management pathways. Current ablation technologies utilize thermal energy to create the necessary lesions to block unnecessary electrical circuits in the heart. However, due to the effect of heat on adjacent structure, the heat (or cold) can also damage these with serious side effects. Common complications fo the procedure are pulmonary vein stenosis, phrenic nerve palsy or oesophageal fistulas...
Arga has developed a new system focused to improve the effectiveness of cardiac ablation for the treatment of Atrial Fibrillation (AF). AF is the second cause of stroke and cardiac ablation is the only treatment today recommended for those that fail treatment with anti-arrhythmic drugs. Despite good acute outcomes of current ablation technologies, the recurrence of AF occurs in 30 to 50% of patients within a year, demanding a new procedure.
Arga has developed a new source of energy that improves on safety and effectiveness of procedure, without having to change the medical procedure or patient management pathways. Current ablation technologies utilize thermal energy to create the necessary lesions to block unnecessary electrical circuits in the heart. However, due to the effect of heat on adjacent structure, the heat (or cold) can also damage these with serious side effects. Common complications fo the procedure are pulmonary vein stenosis, phrenic nerve palsy or oesophageal fistulas, this later one, normally leading to death.
Arga, however, has improved on the management of Pulsed Field Ablation, a non-thermal source of energy, that kills the cell by means of achieving irreversible electroporation and consequently a natural cell death. This therapy is cell specific allowing to destroy cardiac cells without causing any harm to adjacent structures.
Arga has developed the generator needed to manage these short pulses of energy as well as a multi-purpose catheter that allows address all forms of lesions the surgeons commonly do in the EP lab. At present, regular exchange of catheters are needed, increasing time and cost of procedure.
More information

Investors

Employees

David Neale
Admin
David Neale CEO Strategic and pragmatic leader